Dustin Sjuts: Yes. I think there’ll be a lot of similarities in terms of how we look at learning from our providers in that space and ensuring that we have the key opinion leaders aligned with key clinical insights. So like with cervical dystonia, we will have a PrevU launch period, which will allow KOLs to kind of hone in on what is that re-treatment interval that they’d like to bring back that cervical dystonia patient. As you know, with that disease state, there’s a variety of disease progressions that also participate in different units, different €“ or excuse me, different dosages, different treatment intervals. And I think we will we’ll use our PrevU strategy similarly in cervical dystonia to kind of leverage those. I think what’s unique about obviously therapeutics, but specifically cervical dystonia, is obviously the use is fairly concentrated, right?
So we’ll be able to get it in the hands of the KOLs early in PrevU build that data set that’s required to continue to in kind of increase the confidence in the larger population. And with cervical dystonia, a 1,000 CD injectors really make up nearly 70% of the overall volume. So it’s highly concentrated and we’ll focus in those areas first with our deep strategy as well.
Operator: Stacy Ku with Cowen. Your line is open.
Stacy Ku: Hi, thanks for taking our questions and congratulations on the progress. So our first question is around the very early any anecdotal feedback. We understand it’s very early, but we appreciate any commentary from the PrevU program clinicians. We know it’s still early for longevity, but any specific commentary on the onset of efficacy or aesthetic feel, appreciate some details. And then for the second question, we’re wondering if you could add any additional details regarding the pacing on how you get to each level of aesthetic accounts. Maybe provide some timing or metrics around how you’ll expand focus from the 5,000 accounts to the target 10,000 to 15,000 potential aesthetic accounts. What are the logistics as you move through the initial bolus of demand? Thank you.
Mark Foley: Sure. So Stacy, on the anecdotal feedback, we’ve been very encouraged by what we’re hearing from the injectors and from the patients. As you pointed out, we are early €“ we’re €“ what two months into the PrevU program, and so it’s probably early to get any duration feedback per se. But thus far, the patient response has been very consistent with what we would expect and what we’ve seen in the clinical trials. And given the size and the scope of our clinical trial program and some of the Phase 2 work that we’ve done and the area, we would expect that to be very representative of what we’re seeing. And so again, it’s early, but we’re encouraged and it’s continued to reinforce that the strategy we’ve put in place is the right strategy.
In terms of the pacing and the timing and the metrics, we’re going to be a little bit more cautious in terms of what we share for competitive purposes. As you can imagine, it’s a very competitive market that is out there. But what we did say is we would go into this PrevU program for a quarter and then we would initiate our full commercial launch. And so we do expect to kick that off in late March. And as we’ve talked previously, we do think that there’s a better experience or onboarding process that we can deliver here in our Nashville headquarters. And so we’re going to have a bias and an affinity to drive people into Nashville as we think that that’s going to yield more stickiness over time. And so that, that process will start this quarter.
